Guardant Health initiated with an Outperform at Baird

Baird analyst Catherine Schulte initiated coverage of Guardant Health (GH) with an Outperform rating and $120 price target Guardant is a commercial-stage precision oncology company that provides proprietary, liquid biopsy solutions across the cancer care continuum, the analyst tells investors in a research note. The firm likes the company’s s position as a leader in the therapy selection space and sees potential upside optionality across its various pipeline initiatives. Guardant is positioned for attractive growth over the next several years, Baird contends.